Literature DB >> 16608037

Diffuse infiltrative hepatocellular carcinomas in a hepatitis B-endemic area: diagnostic and therapeutic impediments.

Sun-Jung Myung1, Jung-Hwan Yoon, Kang Mo Kim, Geum-Youn Gwak, Yoon Jun Kim, Ji-Won Yu, Jin Wook Chung, Hyo-Suk Lee.   

Abstract

BACKGROUND/AIMS: Clinical features of diffuse infiltrative hepatocellular carcinoma (D-HCC) are distinct from those of mass-forming HCCs, and also dependent on etiologic viruses. Moreover, despite a regular HCC-surveillance in those with chronic liver diseases, patients sometimes present with advanced D-HCCs. Thus, in the present study, we were to assess the risk factors, mode of diagnosis and prognosis of D-HCCs in a hepatitis B virus-endemic area.
METHODOLOGY: From January to June 2003, 35 patients who had been newly diagnosed as having D-HCC were enrolled. Their clinical characteristics were compared with those with other types of HCCs, who had been enrolled during the same period. Survival rates were analyzed using Kaplan-Meier method and Cox proportional hazard model.
RESULTS: D-HCC patients were younger and more commonly positive for HBsAg than those with other types of HCCs. During a regular follow-up, these tumors were not readily detectable in ultrasonography. Transarterial chemoembolization was beneficial in patients with good liver function as compared to supportive care, while this was not evident in those with poor hepatic reserve.
CONCLUSIONS: D-HCCs are not readily diagnosed using ultrasonography. These tumors are mostly resistant to treatment, while transarterial chemoembolization might be applied in patients with good liver function.

Entities:  

Mesh:

Year:  2006        PMID: 16608037

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  14 in total

1.  Incidence and risk factors for surveillance failure in patients with regular hepatocellular carcinoma surveillance.

Authors:  Dong Hyun Sinn; Jieun Yi; Moon Seok Choi; Dongil Choi; Geum-Youn Gwak; Yong-Han Paik; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo
Journal:  Hepatol Int       Date:  2013-07-27       Impact factor: 6.047

Review 2.  Infiltrating hepatocellular carcinoma: seeing the tree through the forest.

Authors:  Aram Demirjian; Peter Peng; Jean-Francois H Geschwind; David Cosgrove; Jacob Schutz; Ihab R Kamel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2011-07-02       Impact factor: 3.452

3.  Diffuse infiltrative hepatocellular carcinoma: assessment of presentation, treatment, and outcomes.

Authors:  Peter J Kneuertz; Aram Demirjian; Amin Firoozmand; Celia Corona-Villalobos; Nikhil Bhagat; Joseph Herman; Andrew Cameron; Ahmet Gurakar; David Cosgrove; Michael A Choti; Jean-Francois H Geschwind; Ihab R Kamel; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2012-04-03       Impact factor: 5.344

4.  Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: A retrospective comparative study.

Authors:  Qiang-Sheng Dai; Hong-Lin Gu; Sheng Ye; Yao-Jun Zhang; Xiao-Jun Lin; Wan Yee Lau; Zhen-Wei Peng; Min-Shan Chen
Journal:  Mol Clin Oncol       Date:  2014-08-18

5.  Is transarterial chemoembolization beneficial for patients with diffuse infiltrative hepatocellular carcinoma?

Authors:  Tsung-Hsing Hung; Chen-Chi Tsai; Chung-Chi Lin; Hsing-Feng Lee; Chi-Jen Chu; Han-Chieh Lin
Journal:  Hepatol Int       Date:  2012-07-27       Impact factor: 6.047

Review 6.  MRI of hepatocellular carcinoma: an update of current practices.

Authors:  Hina Arif-Tiwari; Bobby Kalb; Surya Chundru; Puneet Sharma; James Costello; Rainner W Guessner; Diego R Martin
Journal:  Diagn Interv Radiol       Date:  2014 May-Jun       Impact factor: 2.630

7.  Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma.

Authors:  Neil Mehta; Nicholas Fidelman; Monika Sarkar; Francis Y Yao
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-17       Impact factor: 11.382

8.  Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization.

Authors:  Eun Sun Jang; Jung-Hwan Yoon; Jin Wook Chung; Eun Ju Cho; Su Jong Yu; Jeong-Hoon Lee; Yoon Jun Kim; Hyo-Suk Lee; Chung Yong Kim
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-03       Impact factor: 4.553

9.  Performance of serum α-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass.

Authors:  Stephen L Chan; Frankie Mo; Philip J Johnson; Deyond Y W Siu; Michael H M Chan; Wan Y Lau; Paul B S Lai; Christopher W K Lam; Winnie Yeo; Simon C H Yu
Journal:  HPB (Oxford)       Date:  2013-08-26       Impact factor: 3.647

10.  Diffuse-Type Hepatoma: A Grave Prognostic Marker.

Authors:  Rohan C Siriwardana; Chandika A H Liyanage; Bhagya Gunetilleke; Madunil A Niriella; Janaka de Silva; Anuradha S Dassanayake; Subani P Jayatunge
Journal:  Gastrointest Tumors       Date:  2017-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.